Bosulif better than competitor as first-line treatment in rare leukemia, study finds

Bosulif (bosutinib) has shown superiority over a competitor as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in a Phase III trial.

US pharma giant Pfizer (NYSE: PFE) and its partner, UK-based drug development company Avillion, announced that the BFORE study, which compared Bosulif with imatinib, a drug sold by Switzerland’s Novartis (NOVN: VX) under the name Gleevec, had met its primary endpoint of major molecular response (MMR) at 12 months.

"This is good news for CML patients because additional first-line treatment options allow physicians to tailor therapy based on individual patient considerations"